Detalles de la búsqueda
1.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med;
389(24): 2256-2266, 2023 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37870955
2.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med;
385(13): 1196-1206, 2021 09 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34551229
3.
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol;
187: 128-138, 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38833992
4.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol;
184: 168-177, 2024 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325276
5.
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Cancer;
129(12): 1846-1855, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37060236
6.
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
Gynecol Oncol;
178: 110-118, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37839313
7.
Centralizing surgery for ovarian cancer in a 'non-centralizing' country (Belgium): the UNGO (UCLouvain Network of Gynaecological Oncology) experience.
Int J Gynecol Cancer;
2023 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37844964
8.
Hyperpolarized 13C-Pyruvate to Assess Response to Anti-PD1 Immune Checkpoint Inhibition in YUMMER 1.7 Melanoma Xenografts.
Int J Mol Sci;
24(3)2023 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36768822
9.
Management of metastatic melanoma with new immunotherapy approaches beyond PD-1/CTLA-4 inhibitors.
Curr Opin Oncol;
34(2): 123-130, 2022 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35081051
10.
Metabolic imaging using hyperpolarized 13 C-pyruvate to assess sensitivity to the B-Raf inhibitor vemurafenib in melanoma cells and xenografts.
J Cell Mol Med;
24(2): 1934-1944, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31833658
11.
Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy.
Proc Natl Acad Sci U S A;
111(9): 3502-7, 2014 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24550491
12.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
N Engl J Med;
364(26): 2517-26, 2011 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-21639810
13.
Intraoperative Ketorolac and Outcomes after Ovarian Cancer Surgery.
J Clin Med;
13(6)2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38541772
14.
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Oncologist;
18(11): 1190-1, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24105751
15.
Regression of a melanoma brain metastasis that had appeared after immune checkpoint inhibitor discontinuation: a hypothesis-generating case.
Acta Clin Belg;
78(6): 516-520, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37466163
16.
Towards Characterization of Skin Melanoma in the Clinic by Electron Paramagnetic Resonance (EPR) Spectroscopy and Imaging of Melanin.
Mol Imaging Biol;
2023 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37389709
17.
Hysteroscopic management of molar pregnancy: A series of 36 cases.
Rare Tumors;
15: 20363613231168767, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37035475
18.
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
J Clin Oncol;
41(36): 5536-5549, 2023 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37651655
19.
Optimization of electron paramagnetic resonance imaging for visualization of human skin melanoma in various stages of invasion.
Exp Dermatol;
21(5): 341-6, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22509830
20.
Combined HP 13C Pyruvate and 13C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts.
Biomedicines;
10(3)2022 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35327519